PMC5923252_01
High-power magnification of a tumor specimen shows adenocarcinoma (400x).
ott-11-2303Fig1.jpg
PMC5923252_01_ott-11-2303Fig1.jpg
f1-ott-11-2303
Finally, the patient was diagnosed with lung adenocarcinoma on the left upper lobe with stage IIa (pT2aN1M0), as shown in Figure 1.
Circulating tumor DNA liquid biopsy shows S7689I mutation by the ARMS.
ott-11-2303Fig2.jpg
PMC5923252_01_ott-11-2303Fig2.jpg
f2-ott-11-2303
Amplification Refractory Mutation System was performed. And the result was the same as the surgical specimen two years ago (Figure 2).
Thoracic computed tomography (CT) before taking gefitinib (A); after taking gefitinib, metastases increased widely in both lungs (B); after taking afatinib for one month, the metastases shrank obviously (C).
ott-11-2303Fig3.jpg
PMC5923252_01_ott-11-2303Fig3.jpg
f3-ott-11-2303
One month later, the chest CT scan revealed that the metastases increased widely in both lungs, indicating that gefitinib was of primary resistance (Figure 3A and B). The chest CT scan revealed the metastases shrank obviously after 1 month (Figure 3C).